Download Files:
Orelabrutinib
$250 – $1,800
Products Details
Product Description
– Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK[1][2].
Web ID
– HY-129390
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C26H25N3O3
References
– [1]BTK Inhibitor ICP-022.|[2]Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.
CAS Number
– 1655504-04-3
Molecular Weight
– 427.50
Compound Purity
– 99.90
SMILES
– O=C(C1=CC=C(C2CCN(C(C=C)=O)CC2)N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)N
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Btk
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
